SCHEMBL6281585

SCHEMBL6281585

CCOC(=O)c1cn(-c2ccccn2)c2occc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
RAB9A P51151 1/20 0.47
MAOB P27338 1/20 0.45
PTGS2 P35354 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
SLC11A2 P49281 1/20 0.41
ALDH1A1 P00352 5/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
PIM1 P11309 1/20 0.40
IRAK1 P51617 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281174 0.83 MAOB (0.49) HPGDNPC1MAOBTDP1ALDH1A1
SCHEMBL7175985 0.81 ELANE (0.50) HPGDNPC1TP53RAB9AMAOB
SCHEMBL6281429 0.77 MAOB (0.48) NPC1RAB9AMAOBTDP1ALDH1A1
SCHEMBL6283657 0.77 ALDH1A1 (0.54) HPGDNPC1TP53RAB9ATDP1
SCHEMBL6284441 0.76 LMNA (0.56) HPGDNPC1RAB9AMAOBTDP1
SCHEMBL6282379 0.74 LMNA (0.48) HPGDMAOBTDP1ALDH1A1HTT
SCHEMBL6282519 0.73 TSHR (0.48) MAOBTDP1ALDH1A1LMNAMAPK1
SCHEMBL6285810 0.72 ADRB2 (0.45) HPGDMAOBTDP1ALDH1A1MEN1
SCHEMBL7185413 0.71 PDE4A (0.65) HPGDTDP1ALDH1A1MAPK1KDM4E
SCHEMBL30416390 0.71 HTR3A (0.52) HPGDNPC1TP53RAB9AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878705-B2 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents PFIZER (US) 2005-04-12 US disclosed
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY 2004-12-23 US disclosed
EP-1465895-A2 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-13 EP disclosed
WO-2003059911-A2 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS IL4, ZC3HAV1, IRF3 HPGD 2463/4885NPC1 2194/4885TP53 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.